Hepatitis C: Current Research Drugs
Picture your liver at the center of the Milky Way. Now, the swirling stars are treatments, some closer than others. Drug studies are in orbit like this. Work with me here.
Your Liver = Center of your universe.
Filed = Closest stars, drugs waiting on FDA approval. The red tape wheels grind on.
Phase III = Next out, drugs being tested large-scale for safety and efficacy. Will the virus die before you do?
Phase II = Further away from your liver, drugs shown not to kill people when tested on a small group of sick patients. Cohort is the word. This was me during round two of treatment. Kind of risky here.
Phase I = Compounds (drugs) that don’t kill healthy people crazy enough to volunteer (broke students and new parolees)
Preclinical =A blur of solar dust = test tube, computer chemical structuring, animal studies. Yep, animal testing.
When I was first diagnosed in 1991 with Hepatitis C, there was only one binary star, Interferon and Ribavirin. Finally in 2011 came Telaprevir and Boceprevir. That’s a long time between hits, 20 years. Now the Hep C universe is almost getting crowded, but not yet. The issue is safety and timelines. The barbaric days of Interferon could be phased out (pun intended).
Phases of Current Drug Research: Thanks go to Dr Paul Kwo for this slide
So, this slide represents current studies, phases and the mechanism of action (MOA). Remember that we want at least two drugs with different MOAs in our bodies to avoid virus mutation and resistance. The good news is that there are multiple drug candidates in each category. For further information on any study, go to www.clinicaltrials.gov and enter the drug/compound name. This site will also tell you if the study is enrolling patients and if there is a location close to you. This website rocks. Thank you federal government.
The US research system is business-based, where competition for the patent drives the process. I’m not completely opposed to this system. But it does have drawbacks.
Remember when AIDS researchers were competing to isolate the culprit? France and the US, it was crazy. The two groups still argue about whom was first with what.
The HBO movie And The Band Played On documents government and cultural barriers to a disease connected with a cohort that isn’t mainstream, i.e. HIV and homosexual men. I’m glad the barriers came down a bit faster with Hep C. Initially the cohort was alcoholics and drug addicts. But then the target audience became baby boomers. This was 1. More acceptable and 2. A bigger pool of patients and potential profit.
Obviously the slide above is the star of this blog. Drug companies race to be first with a new drug(s). So why am I speaking of other things? Because I think the days of working in a research vacuum are limited. American drug companies say this is bad. They claim without financial incentive, research will dry up.
But, wouldn’t it be great if companies worked together and combined research efforts? I know, that is a big but. I like big buts…There are novel initiatives include partnering between governmental organizations and industry. The world’s largest such initiative is the Innovative Medicines Initiative (IMI), and examples of major national initiatives are Top Institute Pharma in the Netherlands and Biopeople in Denmark. In the USA it could be the National Institutes of Health (NIH). We used to joke that NIH meant “Not Investigated Here” meaning that the USA insists on its own research. Only science types would joke about such topics. No wonder we have a reputation.
Now picture these studies sharing data. Think of all the time and patient suffering saved by quickly identifying drug-drug and drug-disease interactions. Think about how the winners would rise to the top. I don’t care about the political/social overtones. I am just thinking about patients. This is already happening with cancer research.
I have worked on this blog for a week and still can’t get it right.